# Bivalirudin in Late PCI for Oatients With STEMI

Study · id `cardio:ct-nct04185077` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04185077](<https://clinicaltrials.gov/study/NCT04185077>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04185077

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT04185077. Randomized; no masking; primary purpose treatment. Start 2019-11-30 (anticipated); primary completion 2020-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT04185077, source copy `cardio:ctgov-nct04185077-2019-12-10`, retrieved 2026-10-26)
- Planned start: 2019-11-30 (anticipated) (ClinicalTrials.gov record NCT04185077, source copy `cardio:ctgov-nct04185077-2019-12-10`, retrieved 2026-10-26)
- Primary completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT04185077, source copy `cardio:ctgov-nct04185077-2019-12-10`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT04185077, source copy `cardio:ctgov-nct04185077-2019-12-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04185077-2019-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bivalirudin in Late PCI for Oatients With STEMI
- Acronym: BETTER
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): Bivalirudin
- Intervention (Drug): Heparin
- Lead sponsor: Second Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Second Xiangya Hospital of Central South University (`cardio:org-second-xiangya-hospital-of-central-south-university`)

## Provenance

Content hash: 41bd5b809a1f69c500cffad17fb6b53a6d67521cd08da033f923389453839333
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
